Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
COVID-19
SARS-CoV-2
acute respiratory distress syndrome
cellular therapy
intensive care unit (ICU)
mesenchymal stromal cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
04
2022
accepted:
30
05
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive mechanical ventilation, and remains associated with high mortality. Given their ability to limit inflammation, induce immune cells into a regulatory phenotype and stimulate tissue repair, mesenchymal stromal cells (MSCs) represent a promising therapy for severe and critical COVID-19 disease, which is associated with an uncontrolled immune-mediated inflammatory response. In this phase I-II trial, we aimed to evaluate the safety and efficacy of 3 intravenous infusions of bone marrow (BM)-derived MSCs at 3-day intervals in patients with severe COVID-19. All patients also received dexamethasone and standard supportive therapy. Between June 2020 and September 2021, 8 intensive care unit patients requiring supplemental oxygen (high-flow nasal oxygen in 7 patients, invasive mechanical ventilation in 1 patient) were treated with BM-MSCs. We retrospectively compared the outcomes of these MSC-treated patients with those of 24 matched control patients. Groups were compared by paired statistical tests. MSC infusions were well tolerated, and no adverse effect related to MSC infusions were reported (one patient had an ischemic stroke related to aortic endocarditis). Overall, 3 patients required invasive mechanical ventilation, including one who required extracorporeal membrane oxygenation, but all patients ultimately had a favorable outcome. Survival was significantly higher in the MSC group, both at 28 and 60 days (100% vs 79.2%, p = 0.025 and 100% vs 70.8%, p = 0.0082, respectively), while no significant difference was observed in the need for mechanical ventilation nor in the number of invasive ventilation-free days, high flow nasal oxygenation-free days, oxygen support-free days and ICU-free days. MSC-treated patients also had a significantly lower day-7 D-dimer value compared to control patients (median 821.0 µg/L [IQR 362.0-1305.0] vs 3553 µg/L [IQR 1155.0-6433.5], p = 0.0085). BM-MSC therapy is safe and shows very promising efficacy in severe COVID-19, with a higher survival in our MSC cohort compared to matched control patients. These observations need to be confirmed in a randomized controlled trial designed to demonstrate the efficacy of BM-MSCs in COVID-19 ARDS. (www.ClinicalTrials.gov), identifier NCT04445454.
Sections du résumé
Background
Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive mechanical ventilation, and remains associated with high mortality. Given their ability to limit inflammation, induce immune cells into a regulatory phenotype and stimulate tissue repair, mesenchymal stromal cells (MSCs) represent a promising therapy for severe and critical COVID-19 disease, which is associated with an uncontrolled immune-mediated inflammatory response.
Methods
In this phase I-II trial, we aimed to evaluate the safety and efficacy of 3 intravenous infusions of bone marrow (BM)-derived MSCs at 3-day intervals in patients with severe COVID-19. All patients also received dexamethasone and standard supportive therapy. Between June 2020 and September 2021, 8 intensive care unit patients requiring supplemental oxygen (high-flow nasal oxygen in 7 patients, invasive mechanical ventilation in 1 patient) were treated with BM-MSCs. We retrospectively compared the outcomes of these MSC-treated patients with those of 24 matched control patients. Groups were compared by paired statistical tests.
Results
MSC infusions were well tolerated, and no adverse effect related to MSC infusions were reported (one patient had an ischemic stroke related to aortic endocarditis). Overall, 3 patients required invasive mechanical ventilation, including one who required extracorporeal membrane oxygenation, but all patients ultimately had a favorable outcome. Survival was significantly higher in the MSC group, both at 28 and 60 days (100% vs 79.2%, p = 0.025 and 100% vs 70.8%, p = 0.0082, respectively), while no significant difference was observed in the need for mechanical ventilation nor in the number of invasive ventilation-free days, high flow nasal oxygenation-free days, oxygen support-free days and ICU-free days. MSC-treated patients also had a significantly lower day-7 D-dimer value compared to control patients (median 821.0 µg/L [IQR 362.0-1305.0] vs 3553 µg/L [IQR 1155.0-6433.5], p = 0.0085).
Conclusions
BM-MSC therapy is safe and shows very promising efficacy in severe COVID-19, with a higher survival in our MSC cohort compared to matched control patients. These observations need to be confirmed in a randomized controlled trial designed to demonstrate the efficacy of BM-MSCs in COVID-19 ARDS.
Clinical Trial Registration
(www.ClinicalTrials.gov), identifier NCT04445454.
Identifiants
pubmed: 35860245
doi: 10.3389/fimmu.2022.932360
pmc: PMC9291273
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Oxygen
S88TT14065
Banques de données
ClinicalTrials.gov
['NCT04445454']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
932360Informations de copyright
Copyright © 2022 Grégoire, Layios, Lambermont, Lechanteur, Briquet, Bettonville, Baudoux, Thys, Dardenne, Misset and Beguin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Intensive Care Med. 2021 Jun;36(6):681-688
pubmed: 33663244
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
J Transl Med. 2016 May 20;14(1):145
pubmed: 27207011
Stem Cell Res Ther. 2021 Jan 29;12(1):91
pubmed: 33514427
Respir Res. 2014 Apr 04;15:39
pubmed: 24708472
Stem Cell Rev Rep. 2021 Oct;17(5):1917-1925
pubmed: 34319510
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Stem Cells Int. 2017;2017:5173732
pubmed: 28286525
Stem Cells Dev. 2015 Oct 1;24(19):2269-79
pubmed: 26192403
Lancet Respir Med. 2019 Feb;7(2):154-162
pubmed: 30455077
Ann Intensive Care. 2021 Jul 29;11(1):118
pubmed: 34324073
Stem Cell Res Ther. 2020 Aug 18;11(1):361
pubmed: 32811531
Aging Dis. 2021 Apr 1;12(2):360-370
pubmed: 33815870
Nat Rev Immunol. 2012 Apr 25;12(5):383-96
pubmed: 22531326
Front Immunol. 2022 Mar 18;13:839844
pubmed: 35371003
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Cell Stem Cell. 2008 Feb 7;2(2):141-50
pubmed: 18371435
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Transl Med. 2021 Feb;11(2):e297
pubmed: 33634996
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Infect. 2021 Nov;83(5):581-588
pubmed: 34400219
Curr Stem Cell Rep. 2022;8(2):72-92
pubmed: 35502223
Crit Care. 2020 Dec 14;24(1):691
pubmed: 33317616
Stem Cells Transl Med. 2022 Mar 3;11(1):2-13
pubmed: 35641163
Signal Transduct Target Ther. 2020 Aug 27;5(1):172
pubmed: 32855385
Cells. 2021 May 26;10(6):
pubmed: 34073206
Signal Transduct Target Ther. 2021 Feb 10;6(1):58
pubmed: 33568628
Stem Cells Transl Med. 2021 May;10(5):660-673
pubmed: 33400390
Cell Biol Toxicol. 2020 Feb;36(1):83-102
pubmed: 31485828
Stem Cells Transl Med. 2021 Sep;10(9):1279-1287
pubmed: 34102020
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Crit Care. 2022 Feb 21;26(1):48
pubmed: 35189925
Chest. 2022 Mar;161(3):684-696
pubmed: 34478719
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
Aliment Pharmacol Ther. 2017 Jan;45(2):205-221
pubmed: 27878827
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Lancet Respir Med. 2022 Apr;10(4):327-336
pubmed: 35123660
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Stem Cells. 2007 Sep;25(9):2363-70
pubmed: 17540857
Cell Stem Cell. 2009 Jul 2;5(1):54-63
pubmed: 19570514
Stem Cells Dev. 2016 Jul 15;25(14):1073-83
pubmed: 27226274
Front Immunol. 2020 May 19;11:1091
pubmed: 32574263
PLoS One. 2007 May 02;2(5):e416
pubmed: 17476338
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Crit Care. 2020 Jul 11;24(1):420
pubmed: 32653043
Lancet Infect Dis. 2022 Feb;22(2):209-221
pubmed: 34534511
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141887
Front Immunol. 2019 Apr 02;10:619
pubmed: 31001253
Pain Physician. 2020 Mar;23(2):E71-E83
pubmed: 32214286
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774
Crit Care Explor. 2021 May 19;3(5):e0438
pubmed: 34079951